Rideshare Cuts Colon Cancer Deaths, Saves Costs After Abnormal FIT, Study Finds (AJMC)

A new modeling study published in JAMA Network Open suggests that offering $100 rideshare rides to patients with abnormal fecal immunochemical test (FIT) results nearly doubles colonoscopy completion rates, cutting colorectal cancer (CRC) deaths and saving healthcare costs. By raising completion from 35% to 70%, the intervention reduced CRC incidence by 26%, deaths by 33%, and saved over $330,000 per 1,000 people screened—making rideshare support not only effective but cost-saving. Researchers note real-world trials are still needed to validate these findings.